Skip to main content
Top
Published in: Clinical Rheumatology 8/2007

01-08-2007 | Case Report

Successful treatment of life-threatening intestinal ulcer in Behçet’s disease with infliximab: rapid healing of Behçet’s ulcer with infliximab

Authors: Ji Hyeon Ju, Seung-Ki Kwok, Soo-Hong Seo, Chong-Hyeon Yoon, Ho-Youn Kim, Sung-Hwan Park

Published in: Clinical Rheumatology | Issue 8/2007

Login to get access

Abstract

Behçet’s disease is a chronic, relapsing, multisystem inflammatory disorder characterized predominantly by recurrent orogenital ulcers, skin involvement, and uveitis. Recurrent mucocutaneous lesions may be the only symptom in mild cases, but ocular, gastrointestinal, and central nervous system involvement may occur in severe cases. We report in this study the successful treatment with infliximab of severe life-threatening GI bleeding caused by an ileal ulcer in a patient with Behçet’s disease. Antitumor necrosis factor (TNF) therapy could be an emergency therapeutic option in patients with massively bleeding Behçet’s disease and unstable patients or those with acute bleeding with other TNF-α-mediated autoimmune diseases. Another option for anti-TNF therapy could be as bridging management between conservative and surgical treatment.
Literature
1.
go back to reference International study group for Behçet’s disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080 International study group for Behçet’s disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080
2.
go back to reference Kasahara Y, Tanaka S, Nishino M, Umemura H, Shiraha S, Kuyama T (1981) Intestinal involvement in Behçet’s disease: review of 136 surgical cases in the Japanese literature. Dis Colon Rectum 24:103–106PubMedCrossRef Kasahara Y, Tanaka S, Nishino M, Umemura H, Shiraha S, Kuyama T (1981) Intestinal involvement in Behçet’s disease: review of 136 surgical cases in the Japanese literature. Dis Colon Rectum 24:103–106PubMedCrossRef
3.
go back to reference Haugeberg G, Velken M, Johnsen V (2004) Successful treatment of genital ulcers with infliximab in Behçet’s disease. Ann Rheum Dis 63:744–745PubMedCrossRef Haugeberg G, Velken M, Johnsen V (2004) Successful treatment of genital ulcers with infliximab in Behçet’s disease. Ann Rheum Dis 63:744–745PubMedCrossRef
4.
go back to reference Hassard PV, Binder SW, Nelson V, Vasiliauskas EA (2001) Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet’s disease: a case report. Gastroenterology 120:995–999PubMedCrossRef Hassard PV, Binder SW, Nelson V, Vasiliauskas EA (2001) Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet’s disease: a case report. Gastroenterology 120:995–999PubMedCrossRef
5.
go back to reference Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001) Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet 358:295–296PubMedCrossRef Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001) Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet 358:295–296PubMedCrossRef
6.
go back to reference Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL (2001) Treatment of intestinal Behçet’s syndrome with chimeric tumour necrosis factor alpha antibody. Gut 49:725–728PubMedCrossRef Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL (2001) Treatment of intestinal Behçet’s syndrome with chimeric tumour necrosis factor alpha antibody. Gut 49:725–728PubMedCrossRef
7.
go back to reference Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G (1989) Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet’s disease. Lancet 1:1093–1096PubMedCrossRef Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G (1989) Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet’s disease. Lancet 1:1093–1096PubMedCrossRef
8.
go back to reference Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM (2005) Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 89:533–536PubMedCrossRef Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM (2005) Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 89:533–536PubMedCrossRef
9.
go back to reference Mussack T, Landauer N, Ladurner R, Schiemann U, Goetzberger M, Burchardi C, Folwaczny C, Heldwein W, Hallfeldt K (2003) Successful treatment of cervical esophageal perforation in Behçet’s disease with drainage operation and infliximab. Am J Gastroenterol 98:703–704PubMedCrossRef Mussack T, Landauer N, Ladurner R, Schiemann U, Goetzberger M, Burchardi C, Folwaczny C, Heldwein W, Hallfeldt K (2003) Successful treatment of cervical esophageal perforation in Behçet’s disease with drainage operation and infliximab. Am J Gastroenterol 98:703–704PubMedCrossRef
Metadata
Title
Successful treatment of life-threatening intestinal ulcer in Behçet’s disease with infliximab: rapid healing of Behçet’s ulcer with infliximab
Authors
Ji Hyeon Ju
Seung-Ki Kwok
Soo-Hong Seo
Chong-Hyeon Yoon
Ho-Youn Kim
Sung-Hwan Park
Publication date
01-08-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 8/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-006-0410-3

Other articles of this Issue 8/2007

Clinical Rheumatology 8/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine